Effect of BRCA1 R1325K mutation on proliferation and apoptosis of gallbladder cancer cells

doi:10.3969/j.issn.1674-8115.2023.09.001

Abstract

Abstract:

Objective ·To investigate the effects of breast cancer susceptibility gene 1 (BRCA1) R1325K mutation [arginine (R) to lysine (K) mutation at amino acid 1325] on the proliferation and apoptosis of gallbladder cancer cell lines GBC-SD and NOZ. Methods ·BRCA1 wild-type overexpression lentivirus, BRCA1 R1325K mutation overexpression lentivirus, and negative control lentivirus were used to construct the stable transgenic strains of gallbladder carcinoma, cell lines GBC-SD and NOZ. The cells were divided into the control group without the target gene, the BRCA1 wild-type group, and the BRCA1 R1325K mutation group. The expression of target protein was verified by Western blotting. The BRCA1 R1325K mutant gallbladder cancer cells were treated with 20 μmol/L Olaparib, a BRCA1 mutation inhibitor. Gallbladder cancer cell lines were divided into the control group, the BRCA1 wild-type group, the BRCA1 R1325K mutation group, and the BRCA1 R1325K mutation+Olaparib group according to the target gene expression and whether or not the inhibitor was added. The effect of BRCA1 R1325K mutation on proliferation and clonogenesis ability of gallbladder cancer cell lines GBC-SD and NOZ was observed by CCK8 assay and clonogenesis assay, respectively. The effect of BRCA1 R1325K mutation on apoptosis of gallbladder cancer cell lines GBC-SD and NOZ was observed by TUNEL assay. The expressions of apoptosis-related proteins, cleaved PARP, Bcl-2 and Bax, were detected by Western blotting. The inhibitor Olaparib was used to treat the BRCA1 R1325K mutant gallbladder cancer cell lines GBC-SD and NOZ. The phenotypic changes (promoting proliferation, enhancing clonogenesis and inhibiting apoptosis) induced by BRCA1 R1325K mutation were tested in the presence of Olaparib to determine whether the changes could be reversed by the inhibitor. Results ·The results of CCK8 assay and clonogenesis assay showed that BRCA1 R1325K mutation could promote the proliferation of gallbladder cancer cell lines GBC-SD and NOZ, and improve their clonal formation ability, compared with the control group and the BRCA1 wild-type group. Olaparib inhibited the proliferation of gallbladder cancer cell lines overexpressing BRCA1 R1325K mutation (P<0.05). Through TUNEL and Western blotting, it was found that overexpression of wild-type BRCA1 could induce the apoptosis of gallbladder cancer cell lines GBC-SD and NOZ, compared with the control group. Compared with the control group and the BRCA1 wild-type group, the BRCA1 R1325K mutation group had anti-apoptotic effect, in which the expression of apoptosis-inhibiting protein Bcl-2 increased and the expression of pro-apoptotic protein Bax decreased (P<0.05). Conclusion ·BRCA1 R1325K mutation can promote the proliferation of GBC-SD and NOZ cell lines and inhibit their apoptosis.

Key words: gallbladder cancer, BRCA1, mutation, proliferation, apoptosis

CLC Number:

R735.8

YANG Jingxiao, JIA Ziyao, WU Wenguang, WU Xiangsong, ZHANG Fei, LI Huaifeng, ZHU Yidi, LI Maolan. Effect of BRCA1 R1325K mutation on proliferation and apoptosis of gallbladder cancer cells[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(9): 1071-1079.

Figures/Tables 5

Fig 1 Expression of BRCA1 protein in gallbladder cancer cell lines GBC-SD and NOZ after BRCA1 wild-type and BRCA1 R1325K mutation overexpression lentivirus infection

Fig 2 Effects of BRCA1 R1325K mutation on proliferation of gallbladder cancer cell lines GBC-SD and NOZ

Fig 3 Effects of BRCA1 R1325K mutation on colony formation ability of gallbladder cancer cell lines GBC-SD and NOZ

Fig 4 Effects of BRCA1 R1325K mutation on apoptosis of gallbladder cancer cell lines GBC-SD and NOZ

Fig 5 Effects of BRCA1 R1325K mutation on expression of apoptosis-related proteins in gallbladder cancer cell lines GBC-SD and NOZ

TrendMD

References 39

1	SCHMIDT M A, MARCANO-BONILLA L, ROBERTS L R. Gallbladder cancer: epidemiology and genetic risk associations[J]. Chin Clin Oncol, 2019, 8(4): 31.
2	BAIU I, VISSER B. Gallbladder cancer[J]. JAMA, 2018, 320(12): 1294.
3	MIRANDA-FILHO A, PIÑEROS M, FERRECCIO C, et al. Gallbladder and extrahepatic bile duct cancers in the Americas: incidence and mortality patterns and trends[J]. Int J Cancer, 2020, 147(4): 978-989.
4	SHARMA A, SHARMA K L, GUPTA A, et al. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update[J]. World J Gastroenterol, 2017, 23(22): 3978-3998.
5	LAMARCA A, EDELINE J, MCNAMARA M G, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers[J]. Cancer Treat Rev, 2020, 84: 101936.
6	ROA J C, GARCÍA P, KAPOOR V K, et al. Gallbladder cancer[J]. Nat Rev Dis Primers, 2022, 8: 69.
7	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2021, 71(3): 209-249.
8	YOSHIDA K, MIKI Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage[J]. Cancer Sci, 2004, 95(11): 866-871.
9	NA R, ZHENG S L, HAN M, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death[J]. Eur Urol, 2017, 71(5): 740-747.
10	JOHANNSSON O, LOMAN N, MÖLLER T, et al. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers[J]. Eur J Cancer, 1999, 35(8): 1248-1257.
11	YEHIA L, KEEL E, ENG C. The clinical spectrum of PTEN mutations[J]. Annu Rev Med, 2020, 71: 103-116.
12	WOOSTER R, WEBER B L. Breast and ovarian cancer[J]. N Engl J Med, 2003, 348(23): 2339-2347.
13	NAROD S A. Which genes for hereditary breast cancer?[J]. N Engl J Med, 2021, 384(5): 471-473.
14	DANENBERG E, BARDWELL H, ZANOTELLI V R T, et al. Breast tumor microenvironment structures are associated with genomic features and clinical outcome[J]. Nat Genet, 2022, 54(5): 660-669.
15	KONSTANTINOPOULOS P A, NORQUIST B, LACCHETTI C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline[J]. J Clin Oncol, 2020, 38(11): 1222-1245.
16	SUN S X, BRAZHNIK K, LEE M, et al. Single-cell analysis of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers[J]. J Clin Invest, 2022, 132(5): e148113.
17	FEILOTTER H E, MICHEL C, UY P, et al. BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development[J]. PLoS One, 2014, 9(6): e100068.
18	WERNER H. BRCA1: an endocrine and metabolic regulator[J]. Front Endocrinol (Lausanne), 2022, 13: 844575.
19	MOSCHETTA M, GEORGE A, KAYE S B, et al. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer[J]. Ann Oncol, 2016, 27(8): 1449-1455.
20	FARMER H, MCCABE N, LORD C J, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy[J]. Nature, 2005, 434(7035): 917-921.
21	HARKIN DP, BEAN JM, MIKLOS D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1[J]. Cell, 1999, 97(5): 575-586.
22	PAPADAKI C, TSAROUCHA E, KAKLAMANIS L, et al. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer[J]. Br J Cancer, 2011, 104(2): 316-323.
23	BUSACCA S, SHEAFF M, ARTHUR K, et al. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma[J]. J Pathol, 2012, 227(2): 200-208.
24	DEVICO MARCIANO N, KROENING G, DAYYANI F, et al. BRCA-mutated pancreatic cancer: from discovery to novel treatment paradigms[J]. Cancers, 2022, 14(10): 2453.
25	DE BONO J, MATEO J, FIZAZI K, et al. Olaparib for metastatic castration-resistant prostate cancer[J]. N Engl J Med, 2020, 382(22): 2091-2102.
26	GOLAN T, HAMMEL P, RENI M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4): 317-327.
27	MOORE K, COLOMBO N, SCAMBIA G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med, 2018, 379(26): 2495-2505.
28	HUSSAIN M, MATEO J, FIZAZI K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer[J]. N Engl J Med, 2020, 383(24): 2345-2357.
29	ROBSON M E, TUNG N, CONTE P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician′s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer[J]. Ann Oncol, 2019, 30(4): 558-566.
30	XIE Y, JIANG Y, YANG X B, et al. Response of BRCA1-mutated gallbladder cancer to olaparib: a case report[J]. World J Gastroenterol, 2016, 22(46): 10254-10259.
31	LI X F, GAO L M, QIU M, et al. Olaparib treatment in a patient with advanced gallbladder cancer harboring BRCA1 mutation[J]. Onco Targets Ther, 2021, 14: 2815-2819.
32	OUCHI T, MONTEIRO A N, AUGUST A, et al. BRCA1 regulates p53-dependent gene expression[J]. Proc Natl Acad Sci USA, 1998, 95(5): 2302-2306.
33	ZHANG L, ZHOU Q, QIU Q Z, et al. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer[J]. Mol Cancer, 2019, 18(1): 144.
34	LIU X L, LIU H X, ZENG L, et al. BRCA1 overexpression attenuates breast cancer cell growth and migration by regulating the pyruvate kinase M2-mediated Warburg effect via the PI3K/AKT signaling pathway[J]. PeerJ, 2022, 10: e14052.
35	MIYASHITA T, KRAJEWSKI S, KRAJEWSKA M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo[J]. Oncogene, 1994, 9(6): 1799-1805.
36	MIYASHITA T, HARIGAI M, HANADA M, et al. Identification of a p53-dependent negative response element in the Bcl-2 gene[J]. Cancer Res, 1994, 54(12): 3131-3135.
37	RESHI L, WU H C, WU J L, et al. GSIV serine/threonine kinase can induce apoptotic cell death via p53 and pro-apoptotic gene Bax upregulation in fish cells[J]. Apoptosis, 2016, 21(4): 443-458.
38	DASHZEVEG N, YOSHIDA K. Cell death decision by p53 via control of the mitochondrial membrane[J]. Cancer Lett, 2015, 367(2): 108-112.
39	LAYANI-BAZAR A, SKORNICK I, BERREBI A, et al. Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state[J]. Cancer Res, 2014, 74(11): 3092-3103.

[1]	ZHU Zijun, QIAN Yife, LI Qianyu, LI Songling, QIN Wenli, LIU Yanfeng. Anaphase-promoting complex subunit 10 promotes hepatocellular carcinoma progression through regulation of the PI3K-AKT-mTOR signaling pathway [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1171-1182.
[2]	HE Jiayin, CHEN Siyuan, SHI Qing, ZHANG Muchen, YI Hongmei, DONG Lei, QIAN Ying, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili. Clinicopathologic characteristics, gene mutation profile, and prognostic analysis of patients with adrenal diffuse large B-cell lymphoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1194-1201.
[3]	CHEN Siyuan, SHI Qing, FU Di, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili. Clinicopathologic characteristics, gene mutation profile, and prognostic analysis of diffuse large B-cell lymphoma with lung involvement [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1214-1220.
[4]	YIN Ziming, WANG Rongqin, YANG Ziyi, LIU Yingbin, CHEN Tao, SHU Yijun, GONG Wei. Graph neural network-based auxiliary diagnostic model for gallbladder cancer on CT imaging [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1221-1231.
[5]	JIANG Yi, HUANG Chenhao, LI Zhiliang, WU Junwei, ZHAO Ren, ZHANG Tao. Effect of preoperative chemotherapy combined with immunotherapy in a colorectal cancer patient with KRAS mutation [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1256-1260.
[6]	WANG Gaoming, CUI Ran, LI Yanjing, LIU Yingbin. Study on the mechanism of KRAS R68G secondary mutation-induced resistance to KRAS^G12D-targeted inhibitor MRTX1133 [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(6): 705-716.
[7]	YANG Na, LIU Junli, BAI Jing, YANG Siyi, HAN Jiming, ZHANG Huahua. HENMT1 promotes the proliferation and migration of gastric cancer by activating the PI3K-AKT-mTOR signaling pathway [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(6): 717-726.
[8]	XU Muxin, LIU Xian, JIANG Lishan, SUN Qing. Promotion of Nd:YAP laser biostimulation on the proliferation and osteogenic differentiation of human periodontal ligament cells through WNT/β-catenin signaling pathway [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(5): 562-569.
[9]	CHEN Yinan, ZHENG Yang, ZENG Hanlin, LEI Ming. Mechanism of Fas-associated protein with death domain in promoting proliferation of head and neck squamous cell carcinoma cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(4): 404-414.
[10]	ZHANG Xianzhou, DU Fenglin, WU Lei, REN Yizhe, ZHAO Mingna, LOU Jiatao. Mechanistic study of OGT-promoted non-small cell lung cancer proliferation via the ERK signaling pathway [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(10): 1288-1297.
[11]	LI Xiang, WEI Ming, WU Wenxi, LUO Xiaoqin, YAO Biao, WU Siyu. Inhibitory effect of rutin on the growth and metastasis of osteosarcoma in vitro and in vivo [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(1): 20-28.
[12]	SUN Chenwei, HAI Wangxi, QU Qian, XI Yun. [¹⁸F]F-FMISO and [¹⁸F]F-FLT PET/CT dual-nuclide imaging for in vivo prediction of drug resistance in pancreatic cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(1): 60-68.
[13]	SHI Lingling, CHENG Yanyong, ZHANG Lei. Effects of sevoflurane exposure on proliferation and differentiation of primary oligodendrocytes [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(9): 1115-1123.
[14]	WANG Boen, CHEN Siyuan, SHI Qing, ZHANG Muchen, YI Hongmei, DONG Lei, WANG Li, CHENG Shu, XU Pengpeng, ZHAO Weili. Clinicopathologic characteristics of patients with kidney-involved diffuse large B-cell lymphoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(9): 1162-1168.
[15]	HAN Yishan, XU Ziqi, TAO Mengyu, FAN Guangjian, YU Bo. PRMT6 promotes the proliferation and migration of breast cancer cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(8): 999-1010.